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Ideal Weight, Body Composition and
Lipid Levels: An Unresolved Dilemma?
Osman et al. (1) have shown that in chronic heart failure (CHF),
peak VO2 corrected for lean body mass is a more powerful predictor
of clinical outcome than the traditional peak VO2 adjusted for total
body weight. We thank the authors for addressing this important
issue, since the estimation of exercise capacity is significantly
influenced by body fat content (2). There are, however, several
points we would like to comment upon. In addition to the findings
of Osman et al. (1), we found that mildly obese CHF patients had
a better prognosis (3). Although Osman et al. (1) demonstrated
that subjects reaching the set end points had significantly reduced
body fat mass, they did not provide statistical data regarding the
impact of body fat mass on prognosis. Of note, the majority of
subjects in their study had mild-to-moderate CHF and an average
body weight of 89 kg (BMI [body mass index] 28.9 kg/m2), in
keeping with metabolic stability. However, CHF is increasingly
recognized as a metabolic syndrome with both fat and muscle mass
being reduced during disease progression.
Osman et al. (1) state that fat tissue is metabolically inactive, and
this is certainly true in the setting of acute exercise testing.
Alternatively, fat mass may be an indicator of preserved metabolic
efficiency and/or energy reserve in CHF, and as such may relate to
enhanced survival. Therefore, a mild increase in BMI might not be
considered an adverse risk factor in CHF, and as such we would be
most grateful if Osman et al. (1) could comment on this based on
the data from their study. Obesity, and in particular fat mass, has
primarily been considered to relate to an unfavorable atherogenic
lipoprotein profile, recognized as one of the major risk factors
contributing to the development of ischemic heart disease (IHD).
Whereas patients with IHD are metabolically stable, patients with
CHF can develop substantial catabolism (4).
In view of this, we have hypothesized that low serum cholesterol
may be associated with impaired prognosis in CHF (5). We have
clinical data supporting this hypothesis, which has been presented
recently (6). A recent study by Horne et al. (7) demonstrated that
total cholesterol and atherogenic lipid indices were not predictors
of impaired clinical outcome in severe IHD. However, an elevated
C-reactive protein (a nonspecific marker of systemic inflammation)
and reduced left ventricular ejection fraction (reflecting the pres-
ence of CHF) were independently related to mortality. Thus, in
this study, systemic inflammation but not lipid levels appear to be
linked to increased mortality in CHF. Of note, statin therapy was
associated with marked beneficial effects on clinical outcome,
independently of lipid levels. These findings together lend support
to our hypothesis that, in CHF, higher body fat and serum
cholesterol may relate to enhanced survival, and perhaps statins
actually exert beneficial effects by mechanisms other than lipid-
lowering (5). In addition, they may also increase the turnover of
endotoxin-laden lipoproteins in the plasma by inhibiting endoge-
nous cholesterol synthesis. This might then lead to endotoxin
elimination, reduced cytokine production and, finally, less systemic
immune activation.
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REPLY
We thank Drs. Schmidt and Rauchhaus for their insightful
comments and appreciate the opportunity to delineate the issue of
body fat and prognosis in chronic heart failure (CHF).
In our investigation (1), obesity (body mass index [BMI]
.30 kg/m2) was encountered in 37% of the cohort, with no
statistically significant difference in clinical outcome among the
obese and nonobese (10% of obese patients reached the end point
of death or urgent transplantation compared with 18% of the
nonobese patients, p 5 0.1). Furthermore, although percent fat
was lower in those who reached the primary end point than in
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survivors, the differences were marginal but statistically significant
(p 5 0.02). Additional multivariate analyses of our larger current
database reveal a significant correlation between body fat and
improved prognosis, with a risk ratio (RR) of 0.95 (p 5 0.028).
When we divided patients into quartiles of body fat, the lowest
quartile had an event rate of 11% compared to 5% in those in the
highest quartile, suggesting that weight does indeed appear to
predict outcome in chronic heart failure (p , 0.05).
We agree with the authors that loss of body fat, muscle and bone
mass in severe CHF represent manifestations of the systemic
catabolic nature of the disease process and are markers of neuro-
hormonal and cytotoxic aberrations (2,3). Increased adiposity,
nevertheless, should not be considered salutary in heart failure.
Body fat beyond normal reported ranges and “metabolic stability”
represents an excess burden on an already limited cardiopulmonary
system and is associated with decreases in functional capacity, as
our cardiopulmonary exercise indices suggest. We also wish to
highlight the finding in the authors’ own investigation, which
suggested the best survival in the “mildly” obese group (BMI 28 to
32 kg/m2) compared to worse survival on either side of this
spectrum (BMI .32, RR 1.5, and BMI ,28, RR 1.7) (4).
We read with interest the work of the authors on the relation-
ship of cholesterol and prognosis in heart failure. In an earlier
investigation, our group similarly described the association of low
serum cholesterol in concert with cardiac performance character-
istics as an important independent marker of adverse clinical
outcome and need for mechanical ventricular support (5). More
recently, we have defined the unique association of low high-
density lipoprotein cholesterol with a greater propensity for heart
failure hospitalizations and death (6). High density lipoproteins are
known to interact with cytokine-induced adhesion cell molecule
elucidation and to influence the generation of prostacyclin via
cyclo-oxygenase stimulation; both of these pathophysiologic events
are implicated in the natural history of CHF (7). Thus, the current
scientific evidence appears to point toward an important associa-
tion of inflammation, oxidative stress and lipoprotein metabolism
in heart failure. Whether these findings represent an epiphenom-
enon or therapeutic target remains to be established.
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